Aitia
Yongan Zhao has had a diverse range of work experience in various companies and roles.
Yongan is currently working at GNS Healthcare as a Principal Software Engineer since October 2021. Before that, they held the position of Senior Software Engineer from April 2019 to September 2021, and prior to that, they worked as a Software Engineer from November 2017 to March 2019, all within the same company.
Prior to GNS Healthcare, Yongan was employed at Seven Bridges as an R&D Engineer from March 2016 to October 2017.
Yongan also worked as a Research Assistant at Indiana University Bloomington from September 2009 to December 2015.
In 2013, Yongan gained experience as a Summer Research Intern at Dow AgroSciences.
Yongan'searly work experience includes a role as a Software Engineer at Beijing Lingtu from May 2007 to August 2008.
Yongan Zhao completed a Master's Degree in Bioinformatics at Indiana University Bloomington from 2009 to 2011. Prior to that, they obtained another Master's Degree in Computer Science from Northwestern Polytechnical University from 2004 to 2007. Following their Master's Degree at Indiana University Bloomington, they pursued a Doctor of Philosophy (Ph.D.) in Bioinformatics, with an unspecified end year.
Aitia
1 followers
Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology,neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.